Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


Brajesh Mittal

Brajesh Mittal

Garhoud Private Hospital, UAE

Title: Stent blockage: Different shades of grey


Biography: Brajesh Mittal


Stent blockage has and estimated incidence of 1-5%. It is multifactorial nature and may have devastating consequences viz. AC myocardial infarction/sudden cardiac death, case fatality rate can be as high as 45%. It is prudent to identify those at high risk and should have a clear aim to minimize occurrence. There are several predictors of stent thrombosis and are related to 3 groups: patient, lesion and procedure. Among the most important ones are antiplatelet non-responsiveness, noncompliance or premature cessation. Long lesions/small vessels; stent under expansion. Strongest factors are: Discontinuation OR Dual Antiplatelet Therapy (DAPT), stent under sizing, intermediate lesion proximal to stent, concomitant malignancy, and acute coronary syndrome. Overall early ST >>late ST (>70%). Drug eluting stents also carry the risk of more frequent Very Late Stent Thrombosis (VLST). Underlying pathology depends upon the timing of stent occlusion; while acute and subacute stent occlusion is predominantly thrombotic, later occlusions are more of neo-atherosclerosis. A good mix is being underlying neo-atherosclerosis, thin cap fibroatheroma and thrombus on top. DAPT compliance and procedural optimization are the two most important areas of attention for all the interventional cardiologists to minimize and avoid this potentially devastating complication.